Ketamine: Mechanisms and Relevance to Treatment of Depression.
Ji-Woon Kim, Kanzo Suzuki, E. Kavalali, L. Monteggia
Annual Review of Medicine September 20, 2023 DOI: 10.1146/annurev-med-051322-120608 via Semantic Scholar
Summary
Ketamine produces rapid and sustained antidepressant effects in patients with major depressive disorder that has not responded to conventional monoamine-based drugs. Recent preclinical studies have begun to clarify the mechanisms underlying these effects. This review compares clinical and preclinical findings to provide a broad perspective on how ketamine works as an antidepressant.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Medicine |
| Citations | 105 |
| Key finding | Ketamine shows rapid onset with sustained antidepressant effects in treatment-resistant major depressive disorder. |
Abstract
Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-based antidepressant drugs are a primary line of treatment for this mental disorder, although the delayed response and incomplete efficacy in some patients highlight the need for improved therapeutic approaches. Over the past two decades, ketamine has shown rapid onset with sustained (up to several days) antidepressant effects in patients whose MDD has not responded to conventional antidepressant drugs. Recent preclinical studies have started to elucidate the underlying mechanisms of ketamine's antidepressant properties. Herein, we describe and compare recent clinical and preclinical findings to provide a broad perspective of the relevant mechanisms for the antidepressant action of ketamine. Expected final online publication date for the Annual Review of Medicine, Volume 75 is January 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.